

Rec'd PCT/PTO 19 SEP 2006

Nixon Peabody LLP

Attorneys at Law

100 Summer Street
Boston, Massachusetts 02110-2131
(617) 345-1000

Fax: (617) 345-1300

PRIVILEGE AND CONFIDENTIALITY NOTICE

The information in this fax is intended for the named recipients only. It contains privileged and confidential matter. If you have received this fax in error, please notify us immediately by a collect telephone call to (617) 345-1000 and return the original to the sender by mail. We will reimburse you for postage. Do not disclose the contents to anyone. Thank you.

FAX

To:	Company	Fax #:	Telephone #:
1) To Whom It May Concern	US Receiving Office - PCT Operations	(703) 305-3230	

INTERNATIONAL PHONE NUMBERS MUST INCLUDE COUNTRY & CITY CODE. SEE LOCAL WHITE PAGES FOR CODES NEEDED.

From: Ronald I. Eisenstein Leena H. Karttunen	Date: September 19, 2006	No. of Pages: 16 (including this page)	700953-53676
--	--------------------------	---	--------------

Practitioner's Docket No. 700953-53676

PATENT

IN THE UNITED STATES RECEIVING OFFICE

International Application Number	International Filing Date	International Earliest Priority Date
PCT/US2004/38643	12 November 2004 (12.11.2004)	12 November 2003 (12.11.2003)

U.S. SERIAL NO.: 10/579,025

TITLE OF INVENTION: CUSTOM VECTORS FOR TREATING AND PREVENTING PANCREATIC CANCER

APPLICANT(S) FOR DO/EO/US: Panicali et al.

Mail Stop PCT (U.S. Receiving Office)
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that the following papers are being facsimile transmitted to the United States Patent and Trademark Office at (703) 305-3230 on the date shown below:

1. Facsimile Cover Sheet (1 pg.);
2. Certificate of Facsimile Transmission (1 pg.);
3. Copy of Certificate of Limited Recognition (1pg.);
4. Transmittal Form (3 pg.); and
5. Declaration and Power of Attorney (10pg).

IF YOU DO NOT RECEIVE ALL OF THESE PAGES, PLEASE CONTACT THE FAX OPERATOR AS SOON AS POSSIBLE AT: (617) 345-1386. THANK YOU.

CONFIRMATION: DATE SENT 9/19/06 TIME 10:40am BY MLS

INTEROFFICE TO: ☐ Albany ☐ Boston ☐ Buffalo ☐ Garden City ☐ Hartford ☐ Manchester ☐ New York City
☐ Northern Virginia ☐ Orange County ☐ Providence ☐ Rochester ☐ San Francisco ☐ Washington

To:	Company	Fax #:	Telephone #:
1) To Whom It May Concern	US Receiving Office	(703) 305-3230	

INTERNATIONAL PHONE NUMBERS MUST INCLUDE COUNTRY & CITY CODE. SEE LOCAL WHITE PAGES FOR CODES NEEDED.

From: Ronald I. Eisenstein Leena H. Karttunen	Date: September 19, 2006	No. of Pages: 16 (including this page)	Client/Matter: 700953-53676
User #: 7468	Ext: 6054	Disbursement Amount: S	

Practitioner's Docket No. 700953-53676

PATENT

IN THE UNITED STATES RECEIVING OFFICE

International Application Number	International Filing Date	International Earliest Priority Date
PCT/US2004/38643	12 November 2004 (12.11.2004)	12 November 2003 (12.11.2003)

U.S. SERIAL NO.: 10/579,025

TITLE OF INVENTION: CUSTOM VECTORS FOR TREATING AND PREVENTING PANCREATIC CANCER

APPLICANT(S) FOR DO/EO/US: Panicali et al.

Mail Stop PCT (U.S. Receiving Office)
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Fax: (703) 305-3230

Certificate of Facsimile Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent
and Trademark Office at (703) 305-3230

on September 19, 2006____.
Date

1. Facsimile Cover Sheet (1 pg.);
2. Certificate of Facsimile Transmission (1 pg.);
3. Copy of Certificate of Limited Recognition (1pg.);
4. Transmittal Form (3 pg.); and
5. Declaration and Power of Attorney (10pg).



Signature

Megan L. Stembridge

Typed or printed name of person signing Certificate


**BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE
UNITED STATES PATENT AND TRADEMARK OFFICE**

LIMITED RECOGNITION UNDER 37 CFR § 11.9(b)

Leena H. Karttunen is hereby given limited recognition under 37 CFR §11.9(b) as an employee of Nixon Peabody LLP, to prepare and prosecute patent applications wherein the patent applicant is the client of Nixon Peabody LLP and an attorney or agent of record in the applications is a registered practitioner who is a member of Nixon Peabody LLP. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Leena H. Karttunen ceases to lawfully reside in the United States, (ii) Leena H. Karttunen's employment with Nixon Peabody LLP ceases or is terminated, or (iii) Leena H. Karttunen ceases to remain or reside in the United States on an H-1B visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Limited Recognition No. L0207
Expires: February 11, 2007



Harry I. Moatz
Director of Enrollment and Discipline

FORM PTO-1390 (REV 12-2001)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEYS DOCKET NUMBER 700953-53676
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/579,025
INTERNATIONAL APPLICATION NO. PCT/US2004/38643	INTERNATIONAL FILING DATE 12 November 2004	PRIORITY DATE CLAIMED 12 November 2003	
TITLE OF INVENTION CUSTOM VECTORS FOR TREATING AND PREVENTING PANCREATIC CANCER			
APPLICANT(S) FOR DO/EO/US Panicali et al.			
<p>Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:</p> <ol style="list-style-type: none"> <input type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. <input checked="" type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. <input type="checkbox"/> This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31). <input type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). <input type="checkbox"/> has been communicated by the International Bureau. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> <input type="checkbox"/> is attached hereto. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)). <ol style="list-style-type: none"> <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). <input type="checkbox"/> have been communicated by the International Bureau. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. <input type="checkbox"/> have not been made and will not be made. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). <p>Items 11 to 20 below concern document(s) or information included:</p> <ol style="list-style-type: none"> <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. <input type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> An Application Data Sheet under 37 CFR 1.76. <input type="checkbox"/> A substitute specification. <input checked="" type="checkbox"/> A change of power of attorney and/or address letter. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). <input checked="" type="checkbox"/> Other items or information: Certificate of Facsimile Transmission, Certificate of Limited Recognition (L. H. Karttunen). 			

U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.50)		INTERNATIONAL APPLICATION NO.		ATTORNEYS DOCKET NUMBER	
10/579,025		PCT/US2004/38643		700953-53676	
The following fees are submitted:				CALCULATIONS	PTO USE ONLY
21. <input type="checkbox"/> Basic national fee (37 CFR 1.492(a)).....				\$	
22. <input type="checkbox"/> Examination fee.....				\$	
If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4).....					
All other situations.....					
23. <input type="checkbox"/> Search fee.....				\$	
If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4).....					
Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority.....					
International Search Report prepared by an ISA other than the US and provided to the Office or previously communicated to the US by the IB.....					
All other situations.....					
TOTAL OF 21, 22 and 23 =				\$	
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing in compliance with 37 CFR 1.821(c) or (e) or computer program listing filed in an electronic medium) (37 CFR 1.492(j)). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.					
Total Sheets	Extra sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	RATE		
- 100 =	/50 =		x \$250.00	\$	
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	- 20 =		x \$50.00	\$	
Independent claims	- 3 =		x \$200.00	\$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$360.00	\$	
TOTAL OF ABOVE CALCULATIONS =				\$	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$	
SUBTOTAL =				\$	
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
TOTAL NATIONAL FEE =				\$	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$	
TOTAL FEES ENCLOSED =				\$ 0.00	
				Amount to be refunded:	\$
				Amount to be charged:	\$

- a. ☐ A check in the amount of \$ _____ to cover the above fees is enclosed.
- b. ☐ Please charge my Deposit Account No. 19-2380 in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-2380. A duplicate copy of this sheet is enclosed.
- d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

NIXON PEABODY LLP
100 Summer Street
Boston, MA 02110-2131



SIGNATURE

Ronald I. Eisenstein / Leena H. Karttunen

30,628 / L0207

REGISTRATION NUMBER